Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Preventing serious complications from COVID-19 in potentially vulnerable populations in high risk environments, such as prisons, and preventing spread to surrounding communities needs a coordinated evidence-based approach to managing outbreaks of COVID-19 in prison settings.

3d rendering of coronavirus in prison

Researchers at the University of Oxford, Department of Psychiatry, conducted a systematic review on managing outbreaks of highly contagious diseases in prisons, using 28 studies of investigations, which were all based in high-income countries with documented outbreaks of tuberculosis, influenza (types A and B), varicella, measles, mumps, adenovirus and COVID-19.

A number of challenges specific to managing infectious disease outbreaks in prisons were identified. Contact tracing in prisons is complicated by reluctance to disclose symptoms due to stigma, concerns about confidentiality, and fear of further restrictions, such as prolonged periods of medical isolation. Effective isolation and quarantine measures are difficult due to overcrowding, poor ventilation, sanitation and hygiene, which are common in many prisons. Prisons can easily become a reservoir for COVID-19 infection to the community as turnover is high and transmission can occur at multiple points including via staff. In addition, people in prison have higher rates of many physical and mental health comorbidities, consistently shown to be more common than in community persons of similar age. Thus, the paper recommends a coordinated approach to managing outbreaks in these settings with prisons and public health authorities working closely.

Professor Seena Fazel, Department of Psychiatry, University of Oxford, said,

 

‘Prisons are high-risk settings for the transmission of contagious diseases and there are considerable challenges in managing outbreaks in them. Our research suggests that people in prison should be among the first groups to receive any COVID-19 vaccine to protect against infection and to prevent further spread of the disease. The prison population is generally at higher risk of complications from infection because of the increased prevalence of underlying health conditions, and the overrepresentation of marginalised groups that have been disproportionately affected by COVID-19. A public health approach to managing COVID-19 in prisons is important now and for any future infectious disease outbreaks.’

The research highlights some important actions which health authorities and prisons should do including:

  • Sharing clear and up-to-date information about health risks, prevention and control measures with people in prisons and correctional staff
  • Assessing the benefits of prolonged infection control strategies against the potential negative consequence of such measures on the mental health of the prison population
  • Ensuring that people in prison are released to safe and suitable housing, to ensure that transmission risks are reduced.

According to the New York Times (16 November 2020), more than 252,000 people in prisons and jails have tested positive for COVID-19, and at least 1,450 have died from complications.  In the UK (31 October 2020), the Ministry of Justice reports 55 COVID-related deaths of people in prison. Since the start of the pandemic, there have been 1,529 positive cases in the prison population in England and Wales across 99 establishments.

The research involved a collaboration between infectious diseases and mental health researchers in the US, UK and China, and was partly funded by the Wellcome Trust.

To read the full paper, Managing outbreaks of highly contagious diseases in prisons: a systematic review.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Just Over Half of British Indians Would Get COVID Vaccine

COVID-19 Mental Health

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

Mental Health Schizophrenia

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental Mental Health Worse Since New National Restrictions

COVID-19 Child and adolescent Early intervention Mental Health Psychological therapy

Parental stress, depression, and anxiety have again increased since new national restrictions have been introduced according to the latest report from the Oxford University led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study based on data from over 6000 UK parents.

Potential New Target to Prevent or Delay Dementia

Alzheimer's disease Dementia Mental Health Old-age psychiatry

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.

Over One Quarter of UK Population are Hesitant about COVID-19 Vaccination

COVID-19

The most comprehensive study of COVID-19 vaccine hesitancy to date shows a majority willing to be vaccinated, but a substantial minority concerned. Researchers from the University of Oxford surveyed a representative group of 5,114 UK adults about an approved COVID-19 vaccine for the NHS.

SSRI Treatment in Young People with Depression and Anxiety

Anxiety Depression Mental Health

Results from an insight review commissioned by the Wellcome Trust, highlights what is currently known about the benefits and risks of using selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and anxiety in young people.